At the news
? BULLISHIMPACT 6/10 6-K filed Aug 27, 2026 at 07:30 ET
BrainsWay announced publication of a peer-reviewed secondary analysis in the Journal of Affective Disorders showing a 70% relative reduction in suicidal ideation among MDD patients treated with Deep TMS (from 22.5% to 6.7% over 6 weeks). The data adds to a growing body of 2026 research supporting Deep TMS for suicidality, though the device is not FDA-cleared for this indication. The filing is a clinical-data update without financial figures, providing incremental positive evidence for label expansion potential.
- 70% relative reduction in patients with suicidal ideation (SSI>0) from 22.5% at baseline to 6.7% after 6 weeks of Deep TMS
- Median time to improvement in suicidality was 10 days with SWIFT accelerated protocol vs 13 days with standard protocol (statistically significant)
- Data published in Journal of Affective Disorders as secondary analysis of prior multisite randomized trial that supported FDA clearance of SWIFT in September 2025
- Deep TMS is not FDA-cleared for treatment or prevention of suicidal ideation or behavior
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access